Level C· Early human research exploring benefitsCohort StudyPubMed

Efficacy and safety of freshly collected autologous adipose tissue for complex anal fistulas in non-IBD patients: a prospective cohort study.

Sorensen N., Buntzen S., Pedersen L., Thorlacius-Ussing O.

Cohort Study with a reported sample of 31 on Chronic Wound, Autoimmune Research, published in Tech Coloproctol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
Tech Coloproctol (2026)
Country
Italy
Reported sample size
31
Source database
PubMed
PMID
42149263
DOI
10.1007/s10151-026-03297-6

Abstract (original English)

Complex cryptoglandular anal fistulas present a treatment challenge, with many surgical options associated with recurrence, variable healing rates, and risk of incontinence. Freshly collected autologous adipose tissue (FCAAT) has been proposed as a minimally invasive, one-step alternative. This study aimed to assess clinical healing and clinical improvement and to evaluate the safety of the procedure. This prospective cohort study included 31 patients without inflammatory bowel disease (IBD) with complex single-tract cryptoglandular anal fistulas treated with FCAAT between May 2019 and December 2023 and followed until August 2024. The surgical procedure involved liposuction, processing of adipose tissue, closure of the internal opening, and local injection along the fistula tract in a one-step procedure. Primary outcomes were clinical healing and clinical improvement; secondary outcomes were adverse events. The patient cohort presented with advanced disease. Median disease duration was 20 months, and one-third of patients had undergone previous attempts at surgical closure. Clinical healing was achieved in 23 patients (74%), with an additional four patients (13%) demonstrating clinical improvement. Five of 27 responders (19%) healed more than 3 months post-procedure. Common adverse events included proctalgia in 8 patients (22%), donor site pain 5 (14%), and minor graft site hem

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansRectal FistulaFemaleProspective StudiesMaleAdipose TissueMiddle AgedAdultTreatment OutcomeTransplantation, Autologous

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research